Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 360

1.

Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines - part 2: honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents.

Yarom N, Hovan A, Bossi P, Ariyawardana A, Jensen SB, Gobbo M, Saca-Hazboun H, Kandwal A, Majorana A, Ottaviani G, Pentenero M, Nasr NM, Rouleau T, Lucas AS, Treister NS, Zur E, Ranna V, Vaddi A, Barasch A, Lalla RV, Cheng KKF, Elad S; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology (MASCC/ISOO).

Support Care Cancer. 2020 Feb 13. doi: 10.1007/s00520-019-05256-4. [Epub ahead of print]

PMID:
32056010
2.

Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines.

Saunders DP, Rouleau T, Cheng K, Yarom N, Kandwal A, Joy J, Bektas Kayhan K, van de Wetering M, Brito-Dellan N, Kataoka T, Chiang K, Ranna V, Vaddi A, Epstein J, Lalla RV, Bossi P, Elad S; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO).

Support Care Cancer. 2020 Feb 12. doi: 10.1007/s00520-019-05181-6. [Epub ahead of print]

PMID:
32052137
3.

Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life.

Locati LD, Galbiati D, Calareso G, Alfieri S, Singer S, Cavalieri S, Bergamini C, Bossi P, Orlandi E, Resteghini C, Platini F, Granata R, Quattrone P, Mancinelli M, Mariani L, Lo Vullo S, Licitra LF.

Cancer. 2020 Feb 7. doi: 10.1002/cncr.32754. [Epub ahead of print]

PMID:
32031693
4.

Relevance of apparent diffusion coefficient features for a radiomics-based prediction of response to induction chemotherapy in sinonasal cancer.

Bologna M, Calareso G, Resteghini C, Sdao S, Montin E, Corino V, Mainardi L, Licitra L, Bossi P.

NMR Biomed. 2020 Feb 3:e4265. doi: 10.1002/nbm.4265. [Epub ahead of print]

PMID:
32009265
5.

A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches.

Bossi P, Airoldi M, Aloe Spiriti MA, Antonuzzo A, Bonciarelli G, Campagna A, Cassano A, Murialdo R, Musio D, Silvano G.

Expert Opin Drug Saf. 2020 Feb 6:1-18. doi: 10.1080/14740338.2020.1724955. [Epub ahead of print]

PMID:
32005072
6.

Management of sinonasal adenocarcinomas with anterior skull base extension.

Ferrari M, Bossi P, Mattavelli D, Ardighieri L, Nicolai P.

J Neurooncol. 2020 Jan 3. doi: 10.1007/s11060-019-03385-8. [Epub ahead of print] Review.

PMID:
31897925
7.

Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines.

Correa MEP, Cheng KKF, Chiang K, Kandwal A, Loprinzi CL, Mori T, Potting C, Rouleau T, Toro JJ, Ranna V, Vaddi A, Peterson DE, Bossi P, Lalla RV, Elad S.

Support Care Cancer. 2019 Dec 14. doi: 10.1007/s00520-019-05217-x. [Epub ahead of print]

PMID:
31836937
8.

Is pain part of a systemic syndrome in head and neck cancer?

Bossi P, Ghiani M, Argenone A, Depenni R.

Support Care Cancer. 2020 Feb;28(2):451-459. doi: 10.1007/s00520-019-05147-8. Epub 2019 Nov 12. Review.

PMID:
31713692
9.

Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma.

Mesia R, Bossi P, Hansen AR, Hsieh CY, Licitra LF, Tan EH, Chen P, Miller J, Siu LL, Haddad RI.

Eur J Cancer. 2019 Dec;123:138-145. doi: 10.1016/j.ejca.2019.10.002. Epub 2019 Nov 4.

10.

Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance.

Saba NF, Chen ZG, Haigentz M, Bossi P, Rinaldo A, Rodrigo JP, Mäkitie AA, Takes RP, Strojan P, Vermorken JB, Ferlito A.

Mol Cancer Ther. 2019 Nov;18(11):1909-1915. doi: 10.1158/1535-7163.MCT-19-0214. Review.

PMID:
31676542
11.

Randomized Phase 2 Trial of a Novel Clonidine Mucoadhesive Buccal Tablet for the Amelioration of Oral Mucositis in Patients Treated With Concomitant Chemoradiation Therapy for Head and Neck Cancer.

Giralt J, Tao Y, Kortmann RD, Zasadny X, Contreras-Martinez J, Ceruse P, Arias de la Vega F, Lalla RV, Ozsahin EM, Pajkos G, Mazar A, Attali P, Bossi P, Vasseur B, Sonis S, Henke M, Bensadoun RJ.

Int J Radiat Oncol Biol Phys. 2020 Feb 1;106(2):320-328. doi: 10.1016/j.ijrobp.2019.10.023. Epub 2019 Oct 25.

PMID:
31669562
12.

Clinical Application of a Real-Time Telepathology System for Frozen Section Diagnosis in Comparison With Optical Microscope.

Huang YT, Renne SL, Sollai M, Damiani D, Bossi P, Morenghi E, Roncalli M, Di Tommaso L.

Front Med (Lausanne). 2019 Oct 4;6:215. doi: 10.3389/fmed.2019.00215. eCollection 2019.

13.

Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck Cancer.

Rognoni C, Quaglini S, Vermorken JB, De Cecco L, Licitra L, Bossi P.

Clin Ther. 2019 Dec;41(12):2517-2528.e28. doi: 10.1016/j.clinthera.2019.09.015. Epub 2019 Oct 17.

PMID:
31630814
14.

Quality Assessment in Supportive Care in Head and Neck Cancer.

Bonomo P, Paderno A, Mattavelli D, Zenda S, Cavalieri S, Bossi P.

Front Oncol. 2019 Sep 18;9:926. doi: 10.3389/fonc.2019.00926. eCollection 2019. Review.

15.

Cetuximab in the management of nasopharyngeal carcinoma - a narrative review.

Iqbal MS, Wilkinson D, Tin A, Bossi P, Gradwell-Nelson L, Kovarik J, O'Hara J, Kelly C.

J Laryngol Otol. 2019 Sep 11:1-13. doi: 10.1017/S0022215119001853. [Epub ahead of print]

PMID:
31506113
16.

Postoperative radiotherapy (PORT) for early oral cavity cancer (pT1-2,N0-1): A review.

Ivaldi E, Di Mario D, Paderno A, Piazza C, Bossi P, Iacovelli NA, Incandela F, Locati L, Fallai C, Orlandi E.

Crit Rev Oncol Hematol. 2019 Nov;143:67-75. doi: 10.1016/j.critrevonc.2019.08.003. Epub 2019 Aug 31.

PMID:
31499275
17.

Difficulties in conducting pure academic research, obstacles in data collection and quality of informations: The example of the INTERCEPTOR study.

Merlano M, Denaro N, Benasso M, Licitra L, Bossi P, Locati L, Vecchio S, Bruzzi P.

Oral Oncol. 2019 Oct;97:99-104. doi: 10.1016/j.oraloncology.2019.08.019. Epub 2019 Aug 28.

PMID:
31472438
18.

Prognostic role of primary tumor, nodal neck, and retropharyngeal GTVs for unresectable sinonasal cancers treated with IMRT and chemotherapy.

Ferella L, Cavallo A, Miceli R, Iacovelli NA, Giandini T, Pignoli E, Calareso G, Bossi P, Resteghini C, Gravina GL, Nicolai P, Castelnuovo P, Piazza C, Licitra L, Fallai C, Orlandi E.

Tumori. 2020 Feb;106(1):39-46. doi: 10.1177/0300891619868006. Epub 2019 Aug 27.

PMID:
31451102
19.

A pilot study of a smartphone-based monitoring intervention on head and neck cancer patients undergoing concurrent chemo-radiotherapy.

Zini EM, Lanzola G, Quaglini S, Bossi P, Licitra L, Resteghini C.

Int J Med Inform. 2019 Sep;129:404-412. doi: 10.1016/j.ijmedinf.2019.06.004. Epub 2019 Jul 24.

PMID:
31445284
20.

Psychometric properties of the Italian version of the Speech Handicap Index.

Mozzanica F, Scarponi L, Rota M, Succo G, Crosetti E, Guzzo M, Bossi P, Piazza C, Ottaviani F, Schindler A.

Disabil Rehabil. 2019 Aug 23:1-6. doi: 10.1080/09638288.2019.1655595. [Epub ahead of print]

PMID:
31442082
21.

[Description of adverse events in publications of clinical trials: much room for improvement.]

Di Maio M, Antonuzzo A, Bossi P.

Recenti Prog Med. 2019 Jul-Aug;110(7):323-324. doi: 10.1701/3197.31742. Italian.

PMID:
31379365
22.

Locally advanced epithelial sinonasal tumors: The impact of multimodal approach.

Orlandi E, Cavalieri S, Granata R, Nicolai P, Castelnuovo P, Piazza C, Schreiber A, Turri-Zanoni M, Quattrone P, Miceli R, Infante G, Sessa F, Facco C, Calareso G, Iacovelli NA, Mattavelli D, Paderno A, Resteghini C, Locati LD, Licitra L, Bossi P.

Laryngoscope. 2019 Aug 1. doi: 10.1002/lary.28202. [Epub ahead of print]

PMID:
31369156
23.

Mining of Self-Organizing Map Gene-Expression Portraits Reveals Prognostic Stratification of HPV-Positive Head and Neck Squamous Cell Carcinoma.

Locati LD, Serafini MS, Iannò MF, Carenzo A, Orlandi E, Resteghin C, Cavalieri S, Bossi P, Canevari S, Licitra L, De Cecco L.

Cancers (Basel). 2019 Jul 26;11(8). pii: E1057. doi: 10.3390/cancers11081057.

24.

Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract.

Locati LD, Cavalieri S, Bergamini C, Resteghini C, Alfieri S, Calareso G, Bossi P, Perrone F, Tamborini E, Quattrone P, Granata R, Galbiati D, Platini F, Orlandi E, Mariani L, Licitra L.

Head Neck. 2019 Oct;41(10):3670-3676. doi: 10.1002/hed.25891. Epub 2019 Jul 29.

PMID:
31355973
25.

Could the extreme conformality achieved with proton therapy in paranasal sinuses cancers accidentally results in a high rate of leptomeningeal progression?

Orlandi E, Iacovelli NA, Cavallo A, Resteghini C, Gandola L, Licitra L, Bossi P.

Head Neck. 2019 Oct;41(10):3733-3735. doi: 10.1002/hed.25848. Epub 2019 Jul 17. No abstract available.

PMID:
31313409
26.

Surveillance of Patients with Head and Neck Cancer with an Intensive Clinical and Radiologic Follow-up.

Imbimbo M, Alfieri S, Botta L, Bergamini C, Gloghini A, Calareso G, Orlandi E, Iacovelli NA, Guzzo M, Granata R, Resteghini C, Locati L, Volpi CC, Licitra L, Bossi P.

Otolaryngol Head Neck Surg. 2019 Oct;161(4):635-642. doi: 10.1177/0194599819860808. Epub 2019 Jul 9.

PMID:
31286827
27.

Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines.

Bowen JM, Gibson RJ, Coller JK, Blijlevens N, Bossi P, Al-Dasooqi N, Bateman EH, Chiang K, de Mooij C, Mayo B, Stringer AM, Tissing W, Wardill HR, van Sebille YZA, Ranna V, Vaddi A, Keefe DM, Lalla RV, Cheng KKF, Elad S; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO).

Support Care Cancer. 2019 Oct;27(10):4011-4022. doi: 10.1007/s00520-019-04892-0. Epub 2019 Jul 8.

PMID:
31286233
28.

Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines.

Hong CHL, Gueiros LA, Fulton JS, Cheng KKF, Kandwal A, Galiti D, Fall-Dickson JM, Johansen J, Ameringer S, Kataoka T, Weikel D, Eilers J, Ranna V, Vaddi A, Lalla RV, Bossi P, Elad S; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO).

Support Care Cancer. 2019 Oct;27(10):3949-3967. doi: 10.1007/s00520-019-04848-4. Epub 2019 Jul 8.

PMID:
31286232
29.

The pathogenesis of mucositis: updated perspectives and emerging targets.

Bowen J, Al-Dasooqi N, Bossi P, Wardill H, Van Sebille Y, Al-Azri A, Bateman E, Correa ME, Raber-Durlacher J, Kandwal A, Mayo B, Nair RG, Stringer A, Ten Bohmer K, Thorpe D, Lalla RV, Sonis S, Cheng K, Elad S; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO).

Support Care Cancer. 2019 Oct;27(10):4023-4033. doi: 10.1007/s00520-019-04893-z. Epub 2019 Jul 8. Review.

PMID:
31286231
30.

Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients and clinical practice guidelines.

Ariyawardana A, Cheng KKF, Kandwal A, Tilly V, Al-Azri AR, Galiti D, Chiang K, Vaddi A, Ranna V, Nicolatou-Galitis O, Lalla RV, Bossi P, Elad S; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO).

Support Care Cancer. 2019 Oct;27(10):3985-3995. doi: 10.1007/s00520-019-04888-w. Epub 2019 Jul 8.

PMID:
31286230
31.

Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelines-part 1: vitamins, minerals, and nutritional supplements.

Yarom N, Hovan A, Bossi P, Ariyawardana A, Jensen SB, Gobbo M, Saca-Hazboun H, Kandwal A, Majorana A, Ottaviani G, Pentenero M, Nasr NM, Rouleau T, Lucas AS, Treister NS, Zur E, Ranna V, Vaddi A, Cheng KKF, Barasch A, Lalla RV, Elad S; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology (MASCC/ISOO).

Support Care Cancer. 2019 Oct;27(10):3997-4010. doi: 10.1007/s00520-019-04887-x. Epub 2019 Jul 8.

PMID:
31286229
32.

Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines.

Zadik Y, Arany PR, Fregnani ER, Bossi P, Antunes HS, Bensadoun RJ, Gueiros LA, Majorana A, Nair RG, Ranna V, Tissing WJE, Vaddi A, Lubart R, Migliorati CA, Lalla RV, Cheng KKF, Elad S; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO).

Support Care Cancer. 2019 Oct;27(10):3969-3983. doi: 10.1007/s00520-019-04890-2. Epub 2019 Jul 8.

PMID:
31286228
33.

Development of the MASCC/ISOO clinical practice guidelines for mucositis: an overview of the methods.

Ranna V, Cheng KKF, Castillo DA, Porcello L, Vaddi A, Lalla RV, Bossi P, Elad S; Mucositis Study group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO).

Support Care Cancer. 2019 Oct;27(10):3933-3948. doi: 10.1007/s00520-019-04891-1. Epub 2019 Jul 8.

PMID:
31286227
34.

Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy.

Bossi P, Botta L, Bironzo P, Sonetto C, Musettini G, Sbrana A, Di Giannantonio V, Locati LD, Di Maio M, Antonuzzo A.

Future Oncol. 2019 Jul;15(21):2543-2553. doi: 10.2217/fon-2018-0772. Epub 2019 Jun 26.

PMID:
31240949
35.

May we rely on induction chemotherapy again as a biological selection of radiosensitive head and neck cancer?

Bossi P, Seront E, Machiels JP.

Oral Oncol. 2019 Jul;94:121-122. doi: 10.1016/j.oraloncology.2019.05.011. Epub 2019 May 21. No abstract available.

PMID:
31126715
36.

Prognostic Nomograms in Oral Squamous Cell Carcinoma: The Negative Impact of Low Neutrophil to Lymphocyte Ratio.

Mattavelli D, Lombardi D, Missale F, Calza S, Battocchio S, Paderno A, Bozzola A, Bossi P, Vermi W, Piazza C, Nicolai P.

Front Oncol. 2019 Apr 30;9:339. doi: 10.3389/fonc.2019.00339. eCollection 2019.

37.

PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents.

Cavalieri S, Perrone F, Milione M, Bianco A, Alfieri S, Locati LD, Bergamini C, Resteghini C, Galbiati D, Platini F, Licitra L, Bossi P.

Oncology. 2019;97(2):112-118. doi: 10.1159/000500246. Epub 2019 May 21.

PMID:
31112973
38.

The point of pain in head and neck cancer.

Bossi P, Giusti R, Tarsitano A, Airoldi M, De Sanctis V, Caspiani O, Alterio D, Tartaro T, Alfieri S, Siano M.

Crit Rev Oncol Hematol. 2019 Jun;138:51-59. doi: 10.1016/j.critrevonc.2019.04.001. Epub 2019 Apr 5. Review.

PMID:
31092385
39.

Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting.

Depenni R, Cossu Rocca M, Ferrari D, Azzarello G, Baldessari C, Alù M, Nolé F, Codecà C, Boscolo G, Piccininni M, Cavalieri S, Bossi P.

Eur J Cancer. 2019 Jul;115:4-12. doi: 10.1016/j.ejca.2019.03.022. Epub 2019 May 10.

PMID:
31082692
40.

Identification of potentially druggable molecular alterations in skin adnexal malignancies.

Cavalieri S, Busico A, Capone I, Conca E, Dallera E, Quattrone P, Licitra L, Pruneri G, Bossi P, Perrone F.

J Dermatol. 2019 Jun;46(6):507-514. doi: 10.1111/1346-8138.14889. Epub 2019 Apr 30.

PMID:
31038235
41.

Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature.

Bossi P, Alfieri S, Strojan P, Takes RP, López F, Mäkitie A, Saba NF, Rodrigo JP, Bradford C, Suarez C, Zafereo M, Forastiere AA, Vermorken JB, Quer M, Sanabria A, Simo R, de Bree R, Rinaldo A, Ferlito A.

Crit Rev Oncol Hematol. 2019 May;137:84-91. doi: 10.1016/j.critrevonc.2019.01.018. Epub 2019 Feb 13. Review.

PMID:
31014517
42.

Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?

Cavalieri S, Platini F, Bergamini C, Resteghini C, Galbiati D, Bossi P, Perrone F, Tamborini E, Quattrone P, Licitra L, Locati LD, Alfieri S.

Expert Opin Investig Drugs. 2019 May;28(5):435-443. doi: 10.1080/13543784.2019.1598376. Epub 2019 Apr 4. Review.

PMID:
30897975
43.

A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes.

De Cecco L, Serafini MS, Facco C, Granata R, Orlandi E, Fallai C, Licitra L, Marchesi E, Perrone F, Pilotti S, Quattrone P, Piazza C, Sessa F, Turri-Zanoni M, Battaglia P, Castelnuovo P, Antognoni P, Canevari S, Bossi P.

Oral Oncol. 2019 Mar;90:94-101. doi: 10.1016/j.oraloncology.2019.02.003. Epub 2019 Feb 11.

44.

Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression.

Cavalleri T, Bianchi P, Basso G, Celesti G, Grizzi F, Bossi P, Greco L, Pitrone C, Valtorta E, Mauri G, Truini M, Dall'Olio FG, Brandi G, Sartore-Bianchi A, Ricciardiello L, Torri V, Rimassa L, Siena S, Mantovani A, Malesci A, Laghi L; Alleanza contro il Cancro (ACC) Colorectal Cancer Working Group.

Cancer Immunol Res. 2019 May;7(5):751-758. doi: 10.1158/2326-6066.CIR-18-0661. Epub 2019 Feb 25.

PMID:
30804005
45.

The role of age in treatment-related adverse events in patients with head and neck cancer: A systematic review.

Coca-Pelaz A, Halmos GB, Strojan P, de Bree R, Bossi P, Bradford CR, Rinaldo A, Vander Poorten V, Sanabria A, Takes RP, Ferlito A.

Head Neck. 2019 Jul;41(7):2410-2429. doi: 10.1002/hed.25696. Epub 2019 Feb 9. Review.

PMID:
30737976
46.

Prevalence of Fatigue in Head and Neck Cancer Survivors.

Bossi P, Di Pede P, Guglielmo M, Granata R, Alfieri S, Iacovelli NA, Orlandi E, Guzzo M, Bianchi R, Ferella L, Infante G, Miceli R, Licitra L, Ripamonti CI.

Ann Otol Rhinol Laryngol. 2019 May;128(5):413-419. doi: 10.1177/0003489419826138. Epub 2019 Jan 30.

PMID:
30700107
47.

Systemic treatment in elderly head and neck cancer patients: recommendations for clinical practice.

Szturz P, Bossi P, Vermorken JB.

Curr Opin Otolaryngol Head Neck Surg. 2019 Apr;27(2):142-150. doi: 10.1097/MOO.0000000000000526. Review.

PMID:
30694914
48.

Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and/or metastatic head and neck cancer.

Mennini FS, Marcellusi A, Fabiano G, Platini F, Bossi P.

Head Neck. 2019 Apr;41(4):908-914. doi: 10.1002/hed.25481. Epub 2019 Jan 24.

PMID:
30680828
49.

Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck.

Mirabile A, Miceli R, Calderone RG, Locati L, Bossi P, Bergamini C, Granata R, Perrone F, Mariani L, Licitra L.

Head Neck. 2019 Jun;41(6):1895-1902. doi: 10.1002/hed.25636. Epub 2019 Jan 16.

PMID:
30652392
50.

Role of pretreatment 18F-FDG PET/CT parameters in predicting outcome of non-endemic EBV DNA-related nasopharyngeal cancer (NPC) patients treated with IMRT and chemotherapy.

Alessi A, Lorenzoni A, Cavallo A, Padovano B, Iacovelli NA, Bossi P, Alfieri S, Serafini G, Colombo CB, Cicchetti A, Mira M, Licitra L, Fallai C, Crippa F, Orlandi E.

Radiol Med. 2019 May;124(5):414-421. doi: 10.1007/s11547-018-0980-6. Epub 2018 Dec 17.

PMID:
30560502

Supplemental Content

Support Center